drugset
drugset / Trial / NCT04143321

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

NCT04143321 ↗

Phase 4 Completed 75 enrolled Isfahan University of Medical Sciences
RandomizedParallel-groupTriple-blindTreatment

Summary

this study was aimed to evaluation of antiangial effect of a new fda drug approval on angina in diabetic patient with refractory angina

Timeline

Start
2018-09-10
Primary completion
2019-04-15
Completion
2019-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral

Indications

diabetes mellitus